SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

10047	Companies
204836	Keywords
135093	Articles
108604	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 09/17/2025 at 07:00, 6 months ago

Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Sanofi's brivekimig shows positive results in phase 2a study for hidradenitis suppurativa, presenting clinically meaningful improvements in primary and secondary endpoints in biologic-naïve patients

Sanofi Brivekimig Hidradenitis Suppurativa Phase 2a Study Immune-mediated Diseases
PRESS RELEASE

published on 09/15/2025 at 18:30, 6 months 2 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 09/12/2025 at 18:35, 6 months 5 days ago

Sanofi Publishes Voting Rights Data for August 2025

Voting Rights Actions Financial Markets Sanofi August 2025
PRESS RELEASE

published on 09/12/2025 at 18:30, 6 months 5 days ago

Sanofi: Information concerning the total number of voting rights and shares - August 2025
Sanofi discloses total number of voting rights and shares as per French regulations. Details available on Sanofi's website

Voting Rights Shares French Regulations Disclosure Sanofi
BRIEF

published on 09/11/2025 at 07:05, 6 months 6 days ago

Sanofi Obtains Fast Track Designation for SAR402663 in the United States

FDA Gene Therapy Sanofi Fast Track AMD
BRIEF

published on 08/29/2025 at 23:55, 6 months 19 days ago

Sanofi’s Wayrilz Gets FDA Approval as First BTK Inhibitor for ITP

FDA Approval Sanofi BTK Inhibitor Wayrilz Immune Thrombocytopenia
PRESS RELEASE

published on 08/29/2025 at 23:50, 6 months 19 days ago

Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia. Novel treatment targets BTK through multi-immune modulation to address root causes of ITP, providing rapid and durable platelet response and improved symptoms

Sanofi BTK Inhibitor Wayrilz Immune Thrombocytopenia LUNA 3 Study
PRESS RELEASE

published on 08/25/2025 at 18:30, 6 months 23 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 08/18/2025 at 18:35, 6 months 30 days ago

Sanofi Reports Total Shares and Voting Rights for July 2025

Voting Rights French Commercial Code Shares 2025 Sanofi
PRESS RELEASE

published on 08/18/2025 at 18:30, 6 months 30 days ago

Sanofi: Information concerning the total number of voting rights and shares - July 2025
Sanofi discloses total voting rights and issued shares as per French commercial and stock market regulations. Details available on their website

Voting Rights Shares French Regulations Investor Relations Sanofi

Accesswire

Published on 03/18/2026 at 01:25, 5 hours 30 minutes ago

Zeus North America Mining Corp. Announces Upsizing and Closing of Final Tranche of Private Placement
Published on 03/18/2026 at 00:30, 6 hours 25 minutes ago

Panther Minerals Announces Appointment of Rick Mah as Chief Financial Officer
Published on 03/18/2026 at 00:30, 6 hours 25 minutes ago

Core Critical Metals Corp. Announces Non-Brokered LIFE Offering and Concurrent Private Placement
Published on 03/17/2026 at 23:59, 6 hours 56 minutes ago

Presentation to Swiss Mining Institute Conference
Published on 03/17/2026 at 23:10, 7 hours 45 minutes ago

Redwood AI CEO Louis Dron Featured on Conversations That Matter to Discuss AI Chemistry Platform and Broader Applications

View all ACCESSWIRE

EQS Group

Published on 03/18/2026 at 06:30, 25 minutes ago

The 2025 annual results reflect developments in the companies and investments under the umbrella of TX Group AG
Published on 03/18/2026 at 06:30, 25 minutes ago

Orell Füssli AG: Orell Füssli reports successful financial year 2025
Published on 03/17/2026 at 23:43, 7 hours 12 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3C - Daily buy back notice
Published on 03/17/2026 at 21:21, 9 hours 34 minutes ago

KION GROUP AG successfully places a bond of € 500 million
Published on 03/17/2026 at 20:55, 9 hours 59 minutes ago

EQS-Adhoc: thyssenkrupp nucera lowers its sales and EBIT outlook for the Group and the gH2 segment for FY 2025/26 due to higher project costs

Les Echos

Published on 03/17/2026 at 07:00, 23 hours 55 minutes ago

Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 12 hours ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 12 hours ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 12 hours ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 1 day 13 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE